Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to a KRAS G12D inhibitor that is on the cusp of the clinic.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive global rights to a KRAS G12D inhibitor developed by San Diego-based Kumquat that is on the brink of starting human trials in the US.

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat Biosciences’ small-molecule KRAS G12D blocker.

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor.

BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.

Berlin: Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, have announced that they have entered into an exclusive global license and collaboration to develop and

Retail traders cooled on Bayer shares Tuesday after the company unveiled a big-ticket partnership with Kumquat Biosciences to develop a new cancer drug aimed at one of oncology’s toughest genetic targets.